MX2022015948A - Proteínas de unión anti-ctla-4 y métodos de uso de estas. - Google Patents

Proteínas de unión anti-ctla-4 y métodos de uso de estas.

Info

Publication number
MX2022015948A
MX2022015948A MX2022015948A MX2022015948A MX2022015948A MX 2022015948 A MX2022015948 A MX 2022015948A MX 2022015948 A MX2022015948 A MX 2022015948A MX 2022015948 A MX2022015948 A MX 2022015948A MX 2022015948 A MX2022015948 A MX 2022015948A
Authority
MX
Mexico
Prior art keywords
methods
ctla
binding proteins
abps
homologs
Prior art date
Application number
MX2022015948A
Other languages
English (en)
Inventor
David Scott Johnson
Adam Shultz Adler
Rena Aviva Mizrahi
Yoong Wearn Lim
Michael Asensio
Erica Lyn Stone
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of MX2022015948A publication Critical patent/MX2022015948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En este documento se proporcionan proteínas de unión al antígeno (ABP) que se unen selectivamente al CTLA-4 y a sus isoformas y homólogos, y composiciones que comprenden las ABP. También se proporcionan métodos para utilizar las ABP, como métodos terapéuticos y de diagnóstico.
MX2022015948A 2020-07-02 2021-07-02 Proteínas de unión anti-ctla-4 y métodos de uso de estas. MX2022015948A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047785P 2020-07-02 2020-07-02
US202063107376P 2020-10-29 2020-10-29
PCT/US2021/040379 WO2022006557A2 (en) 2020-07-02 2021-07-02 Anti-ctla-4 binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022015948A true MX2022015948A (es) 2023-04-05

Family

ID=79317832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015948A MX2022015948A (es) 2020-07-02 2021-07-02 Proteínas de unión anti-ctla-4 y métodos de uso de estas.

Country Status (10)

Country Link
US (1) US20230265192A1 (es)
EP (1) EP4175981A2 (es)
JP (1) JP2023532136A (es)
KR (1) KR20230033719A (es)
CN (1) CN116234821A (es)
AU (1) AU2021299338A1 (es)
CA (1) CA3184082A1 (es)
IL (1) IL298825A (es)
MX (1) MX2022015948A (es)
WO (1) WO2022006557A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4362981A1 (en) * 2021-07-02 2024-05-08 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20110166335A1 (en) * 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018157147A1 (en) * 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
KR20210121045A (ko) * 2018-12-27 2021-10-07 기가젠, 인코포레이티드 항-ctla-4 결합 단백질 및 이의 사용 방법

Also Published As

Publication number Publication date
WO2022006557A3 (en) 2022-02-10
WO2022006557A2 (en) 2022-01-06
IL298825A (en) 2023-02-01
US20230265192A1 (en) 2023-08-24
CN116234821A (zh) 2023-06-06
AU2021299338A1 (en) 2023-02-23
CA3184082A1 (en) 2022-01-06
WO2022006557A8 (en) 2022-03-10
EP4175981A2 (en) 2023-05-10
KR20230033719A (ko) 2023-03-08
JP2023532136A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
WO2018217940A3 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2021007692A (es) Proteinas de union anti-pd-1 y metodos de uso de las mismas.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
MX2021001841A (es) Anticuerpos anti-gdf15, composiciones y metodos de uso.
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PH12019501108A1 (en) Anti-gitr anti-binding protein and methods of use thereof
PH12020551447A1 (en) Antibodies
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
MX2022002682A (es) Anticuerpos anti-cd73.
MX2021015974A (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
AU2020380603A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
WO2022006555A3 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
MX2022015948A (es) Proteínas de unión anti-ctla-4 y métodos de uso de estas.
AU2018279184A1 (en) Anti-TrkB antibodies
MX2021007846A (es) Proteinas que se unen a anti-pd-l1 y metodos de uso de las mismas.
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
MX2022014736A (es) Anticuerpos anti-cd200r1 y metodos de uso de estos.
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40